KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Astrid LièvrePierre Laurent-Puig

Abstract

Cetuximab is efficient in advanced colorectal cancer (CRC). We previously showed that KRAS mutations were associated with resistance to cetuximab in 30 CRC patients. The aim of this study was to validate, in an independent larger series of 89 patients, the prognostic value of KRAS mutations on response to cetuximab and survival. Eighty-nine metastatic CRC patients treated with cetuximab after treatment failure with irinotecan-based chemotherapy were analyzed for KRAS mutation by allelic discrimination on tumor DNA. The association between KRAS mutations and tumor response, skin toxicity, progression-free survival (PFS) and overall survival (OS) was analyzed. A KRAS mutation was present in 27% of the patients and was associated with resistance to cetuximab (0% v 40% of responders among the 24 mutated and 65 nonmutated patients, respectively; P < .001) and a poorer survival (median PFS: 10.1 v 31.4 weeks in patients without mutation; P = .0001; median OS: 10.1 v 14.3 months in patients without mutation; P = .026). When we pooled these 89 patients with patients from our previous study, the multivariate analysis showed that KRAS status was an independent prognostic factor associated with OS and PFS, whereas skin toxicity was only a...Continue Reading

References

May 20, 1998·Journal of the National Cancer Institute·H J AndreyevP A Clarke
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Sep 5, 2001·British Journal of Cancer·H J AndreyevN Urosevic
Oct 29, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U McDermottP G Johnston
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergSteven R Alberts
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzRobert J Mayer
Jul 23, 2004·The New England Journal of Medicine·Deborah Schrag
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Jan 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ki Young ChungLeonard B Saltz
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel VallböhmerHeinz-Josef Lenz
Mar 10, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M FrancoualG Milano
Apr 19, 2006·Cancer Research·Astrid LièvrePierre Laurent-Puig
Oct 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heinz-Josef LenzEric K Rowinsky

❮ Previous
Next ❯

Citations

Apr 22, 2008·Molecular Diagnosis & Therapy·Veena ShankaranAl B Benson
Feb 18, 2009·International Journal of Colorectal Disease·Emmanuel MitryPhilippe Rougier
Mar 24, 2010·International Journal of Colorectal Disease·Ezzeldin M IbrahimBakr M Bin Sadiq
Feb 3, 2011·International Journal of Colorectal Disease·Fausto PetrelliSandro Barni
Jun 2, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Mario E LacoutureUNKNOWN MASCC Skin Toxicity Study Group
Oct 18, 2011·International Journal of Clinical Oncology·Toshiaki WatanabeUNKNOWN Japanese Society for Cancer of the Colon and Rectum
Dec 5, 2008·Apoptosis : an International Journal on Programmed Cell Death·Cao YangZhenfeng Duan
Mar 8, 2011·Clinical & Experimental Metastasis·Teodora Evgenieva GoranovaKikuya Kato
Nov 17, 2009·Targeted Oncology·Fortunato CiardielloDemetris Papamichael
May 7, 2013·Targeted Oncology·Hans PrenenEric Van Cutsem
Jan 30, 2013·Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu·Jing GaoLin Shen
Feb 25, 2009·Current Treatment Options in Oncology·Marwan Fakih
Apr 8, 2011·Current Treatment Options in Oncology·Andrea Cercek, Leonard Saltz
Apr 6, 2011·Gastrointestinal Cancer Research : GCR·Majed El ZouhairiMichael J Pishvaian
Apr 2, 2009·Current Oncology Reports·Robin Kelley, Alan P Venook
Apr 29, 2010·Current Oncology Reports·Andrea Cercek, Leonard Saltz
Apr 29, 2010·Current Oncology Reports·Deepa T PatilThomas P Plesec
Jan 23, 2008·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J de Castro-CarpeñoM González Barón
Nov 18, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Jose A García-SáenzEduardo Díaz-Rubio García
Aug 17, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Jesús García-Foncillas, Eduardo Díaz-Rubio
Mar 23, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Enrique ArandaEduardo Díaz-Rubio
Apr 2, 2010·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Marika Nestor
Nov 26, 2010·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Xabier Garcia-AlbenizJoan Maurel
Oct 12, 2012·Cellular Oncology (Dordrecht)·Cristina García-InclánMario A Hermsen
Sep 21, 2013·Cancer Letters·Tze-Kiong ErMarta Herreros-Villanueva
Feb 5, 2013·Cancer Treatment Reviews·Francesco TorinoAngelo Aquino
Jan 28, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Florence Boissière-MichotFrédéric Bibeau
May 8, 2008·Nature Clinical Practice. Oncology·Jim Cassidy
Mar 23, 2012·Nature Reviews. Cancer·Andrew M ScottLloyd J Old

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.